

Alexander G G Turpie

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7205918/publications.pdf>

Version: 2024-02-01

43
papers

2,863
citations

279798

23
h-index

265206

42
g-index

43
all docs

43
docs citations

43
times ranked

4006
citing authors

#	ARTICLE	IF	CITATIONS
1	Predictive and Associative Models to Identify Hospitalized Medical Patients at Risk for VTE. <i>Chest</i> , 2011, 140, 706-714.	0.8	401
2	XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. <i>European Heart Journal</i> , 2016, 37, 1145-1153.	2.2	383
3	Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry. <i>PLoS ONE</i> , 2013, 8, e63479.	2.5	375
4	Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. <i>Heart</i> , 2017, 103, 307-314.	2.9	205
5	International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). <i>American Heart Journal</i> , 2012, 163, 13-19.e1.	2.7	195
6	International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. <i>American Heart Journal</i> , 2017, 194, 132-140.	2.7	161
7	Trends in Prescribing Oral Anticoagulants in Canada, 2008-2014. <i>Clinical Therapeutics</i> , 2015, 37, 2506-2514.e4.	2.5	124
8	Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. <i>PLoS ONE</i> , 2016, 11, e0164076.	2.5	118
9	Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. <i>BMJ Open</i> , 2017, 7, e017157.	1.9	92
10	Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation. <i>PLoS ONE</i> , 2018, 13, e0191592.	2.5	80
11	Characteristics and Management of Patients with Venous Thromboembolism: The GARFIELD-VTE Registry. <i>Thrombosis and Haemostasis</i> , 2019, 119, 319-327.	3.4	76
12	Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial Fibrillation. <i>Circulation</i> , 2019, 139, 787-798.	1.6	60
13	Global Prospective Safety Analysis of Rivaroxaban. <i>Journal of the American College of Cardiology</i> , 2018, 72, 141-153.	2.8	48
14	ABC of antithrombotic therapy: Venous thromboembolism: treatment strategies. <i>BMJ: British Medical Journal</i> , 2002, 325, 948-950.	2.3	40
15	Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 129.	7.4	37
16	Impact of Switching From a Vitamin K Antagonist to Rivaroxaban on Satisfaction With Anticoagulation Therapy: The XANTUS-FACTS Substudy. <i>Clinical Cardiology</i> , 2016, 39, 565-569.	1.8	33
17	Predictive value of venous thromboembolism (VTE) <sc>BLEED</sc> to predict major bleeding and other adverse events in a practice-based cohort of patients with VTE: results of the XALIA study. <i>British Journal of Haematology</i> , 2018, 183, 457-465.	2.5	32
18	Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry. <i>Blood Advances</i> , 2021, 5, 1081-1091.	5.2	30

#	ARTICLE	IF	CITATIONS
19	XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation. <i>Vascular Health and Risk Management</i> , 2014, 10, 425.	2.3	29
20	Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 70-79.	3.0	29
21	New artificial intelligence prediction model using serial prothrombin time international normalized ratio measurements in atrial fibrillation patients on vitamin K antagonists: GARFIELD-AF. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 301-309.	3.0	29
22	Benefit–risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty. <i>Vascular Health and Risk Management</i> , 2014, 10, 157.	2.3	28
23	Upper Extremity DVT versus Lower Extremity DVT: Perspectives from the GARFIELD-VTE Registry. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1365-1372.	3.4	28
24	Venous Thromboembolism Risk in Ischemic Stroke Patients Receiving Extended-Duration Enoxaparin Prophylaxis: Results From the EXCLAIM Study. <i>Stroke</i> , 2013, 44, 249-251.	2.0	26
25	The association between patterns of atrial fibrillation, anticoagulation, and cardiovascular events. <i>Europace</i> , 2020, 22, 195-204.	1.7	22
26	Effectiveness and Safety of Rivaroxaban Versus Warfarin in Frail Patients with Venous Thromboembolism. <i>American Journal of Medicine</i> , 2018, 131, 933-938.e1.	1.5	21
27	Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 64-69.	3.0	19
28	GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, 8, 214-227.	4.0	19
29	XANTUS-EL: A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Eastern Europe, Middle East, Africa and Latin America. <i>Egyptian Heart Journal</i> , 2018, 70, 307-313.	1.2	17
30	Comparative effectiveness of oral anticoagulants in everyday practice. <i>Heart</i> , 2021, 107, 962-970.	2.9	14
31	Advances in oral anticoagulation treatment: the safety and efficacy of rivaroxaban in the prevention and treatment of thromboembolism. <i>Therapeutic Advances in Hematology</i> , 2012, 3, 309-323.	2.5	13
32	Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELDâ€AF and treated with vitamin K antagonists. <i>British Journal of Haematology</i> , 2016, 174, 610-623.	2.5	13
33	Outcomes after catheter ablation and cardioversion in patients with non-valvular atrial fibrillation: results from the prospective, observational XANTUS study. <i>Europace</i> , 2018, 20, e87-e95.	1.7	13
34	Effectiveness and safety of rivaroxaban versus warfarin in patients with provoked venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 339-345.	2.1	10
35	Real-world vs. randomized trial outcomes in similar populations of rivaroxaban-treated patients with non-valvular atrial fibrillation in ROCKET AF and XANTUS. <i>Europace</i> , 2019, 21, 421-427.	1.7	10
36	Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AF. <i>American Journal of Medicine</i> , 2019, 132, 1431-1440.e7.	1.5	8

#	ARTICLE	IF	CITATIONS
37	Do baseline characteristics and treatments account for geographical disparities in the outcomes of patients with newly diagnosed atrial fibrillation? The prospective GARFIELD-AF registry. <i>BMJ Open</i> , 2022, 12, e049933.	1.9	8
38	Effectiveness and safety of outpatient rivaroxaban versus warfarin for treatment of venous thromboembolism in patients with a known primary hypercoagulable state. <i>Thrombosis Research</i> , 2018, 163, 132-137.	1.7	7
39	Future therapeutic directions for factor Xa inhibition in the prophylaxis and treatment of thrombotic disorders. <i>American Journal of Health-System Pharmacy</i> , 2003, 60, S20-S24.	1.0	5
40	Setting a standard for venous thromboembolism prophylaxis. <i>American Journal of Health-System Pharmacy</i> , 2001, 58, S18-S23.	1.0	2
41	Impact of gender: Rivaroxaban for patients with atrial fibrillation in the <scp>XANTUS</scp> real-world prospective study. <i>Clinical Cardiology</i> , 2020, 43, 1405-1413.	1.8	2
42	Antithrombotic Therapy Following Heart Valve Replacement. <i>Thrombosis and Haemostasis</i> , 1997, 78, 382-385.	3.4	1
43	Oral anticoagulant use in addition to antiplatelet therapy for secondary prevention in acute coronary syndrome: current perspectives. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 963-976.	1.5	0